Hairy Cell Leukemia
📧 Sign up to get email alerts when something new happens for Hairy Cell Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-05-15Clinical Trial Update: Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy [Phase 2]
Phase 2 trial evaluating Rituximab in patients with refractory or recurrent hairy cell leukemia after cladribine therapy has completed.
-
CLINICAL_TRIALS trial_result · 2012-05-01Clinical Trial Update: Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia [Phase 2]
Phase 2 retreatment trial of BL22 immunotherapy in patients with relapsed or refractory Hairy Cell Leukemia was terminated, with results pos…
-
CLINICAL_TRIALS trial_result · 2011-02-21Clinical Trial Update: Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
This completed clinical trial evaluated a method to detect residual disease in blood and bone marrow of patients with previously treated hai…
-
CLINICAL_TRIALS trial_result · 2010-06-22Clinical Trial Update: BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia [Phase 2]
Phase 2 clinical trial of BL22 immunotoxin in hairy cell leukemia patients previously treated with cladribine has completed.
-
FDA approval · 2009-09-22FDA Approved: NIPENT — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Nipent (pentostatin) submitted by Hospira, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2008-03-04Clinical Trial Update: A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia [Phase 2]
Completed Phase II efficacy trial of Roferon-A (interferon alfa-2a) for hairy cell leukemia; study results addressing efficacy have been rep…
-
CLINICAL_TRIALS trial_result · 2007-04-18Clinical Trial Update: Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease [Phase 1]
This is a Phase 1 safety study update for CAT-8015 immunotoxin in patients with hairy cell leukemia with advanced disease.